ストックスクリーナーアプリを入手
0.9192
11.61%
-0.1208
前日終値:
$1.04
開ける：
$1.03
24時間の取引高:
1.05M
Relative Volume:
0.84
時価総額：
$90.10M
収益：
$190.00K
当期純損益:
$-74.12M
株価収益率:
-1.1545
EPS:
-0.7962
ネットキャッシュフロー:
$-62.06M
1週間 パフォーマンス:
+13.85%
1か月 パフォーマンス:
+15.61%
6か月 パフォーマンス:
+12.53%
1年 パフォーマンス:
-70.91%
1日の値動き範囲:
$0.90
$1.03
1週間の範囲:
$0.811
$1.05
52週間の値動き範囲:
$0.64
$7.2904
Atyr Pharma Inc Stock (ATYR) Company Profile
名前
Atyr Pharma Inc
セクター
電話
(858) 731-8389
住所
10240 SORRENTO VALLEY ROAD, SAN DIEGO
Compare ATYR vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ATYR
Atyr Pharma Inc
|
0.9189 | 101.97M | 190.00K | -74.12M | -62.06M | -0.7962 |
VRTX
Vertex Pharmaceuticals Inc
|
426.32 | 108.54B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
710.25 | 75.59B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
781.72 | 50.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.00 | 40.45B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
315.66 | 32.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Atyr Pharma Inc Stock (ATYR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-09-16 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-09-15 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2025-09-15 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2025-09-15 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2025-09-15 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2025-02-18 | 開始されました | Leerink Partners | Outperform |
| 2025-01-06 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-10-04 | 開始されました | Wells Fargo | Overweight |
| 2024-09-05 | 開始されました | Jefferies | Buy |
| 2023-07-05 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2021-10-12 | 開始されました | RBC Capital Mkts | Outperform |
| 2021-09-21 | 開始されました | Piper Sandler | Overweight |
| 2021-05-10 | 開始されました | Laidlaw | Buy |
| 2020-08-17 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2020-03-04 | 開始されました | ROTH Capital | Buy |
| 2020-03-02 | 開始されました | Oppenheimer | Outperform |
| 2018-02-14 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2017-09-07 | 開始されました | Piper Jaffray | Overweight |
| 2016-12-13 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2015-12-16 | 開始されました | Citigroup | Neutral |
| 2015-06-01 | 開始されました | Citigroup | Buy |
| 2015-06-01 | 開始されました | JP Morgan | Overweight |
すべてを表示
Atyr Pharma Inc (ATYR) 最新ニュース
MSN Money - MSN
Facioscapulohumeral Muscular Dystrophy Market: Pharma Pipeline Fuels Rapid Expansion – DelveInsight | Dyne Therapeutics, miRecule, Avidity Biosciences, aTyr Pharma, Fulcrum Therapeutics - Barchart.com
aTyr Pharma (ATYR) Projected to Post Earnings on Wednesday - MarketBeat
Interstitial Lung Disease Pipeline Grows as 120+ Pharma - openPR.com
What is the growth outlook for aTyr Pharma (ATYR) stock (Range-Bound) 2026-04-20Entry Points - Xã Thanh Hà
aTyr Pharma Inc stock (US53227K1025): Is efzofitimod's Phase 3 data the real test for pulmonary sarc - AD HOC NEWS
aTyr Pharma stock tanks after missing main goal in lung disease study - MSN
aTyr Pharma (ATYR) Stock: This Quarter (Near Highs) 2026-04-20Community Chart Signals - Cổng thông tin điện tử Tỉnh Sơn La
aTyr Pharma, Inc. (NASDAQ:ATYR) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
aTyr Pharma (ATYR) Stock Commodity Trade (Investors Pile In) 2026-04-18Shared Momentum Picks - Cổng thông tin điện tử tỉnh Lào Cai
aTyr Pharma, Inc. (ATYR) Stock Analysis: Understanding the 417% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
aTyr Pharma (ATYR) Stock: Overpriced? (Touches High) 2026-04-15Social Trading Insights - Cổng thông tin điện tử tỉnh Lào Cai
aTyr Pharma Inc stock (US53227K1025): Is efzofitimod's pulmonary sarcoidosis data strong enough to u - AD HOC NEWS
Gainers Report: Is aTyr Pharma Inc a momentum stock2026 Recap & Reliable Breakout Stock Forecasts - baoquankhu1.vn
Can aTyr Pharma (ATYR) Stock increase dividends | Price at $0.77, Down 3.64%Most Discussed Stocks - UBND thành phố Hải Phòng
Interstitial Lung Disease Market to Witness Accelerated Growth at a CAGR of 8.7% During the Forecast Period (2026–2036) Due to the Launch of Emerging Therapies | DelveInsight - GlobeNewswire Inc.
Analysts Offer Insights on Healthcare Companies: aTyr Pharma (ATYR) and Idexx Laboratories (IDXX) - The Globe and Mail
Market Wrap: Is aTyr Pharma Inc in a bullish channelM&A Rumor & Comprehensive Market Scan Insights - baoquankhu1.vn
ATYR Technical Analysis & Stock Price Forecast - Intellectia AI
Downgrade Watch: Is aTyr Pharma Inc backed by strong institutional buying2026 Stock Rankings & Daily Growth Stock Investment Tips - baoquankhu1.vn
Performance Recap: Is aTyr Pharma Inc in a bullish channel2026 Momentum Check & Free Technical Confirmation Trade Alerts - baoquankhu1.vn
aTyr Pharma (NASDAQ: ATYR) seeks approval to double share authorization - Stock Titan
[ARS] aTYR PHARMA INC SEC Filing - stocktitan.net
Vanguard disaggregates holdings; reports 0 shares in aTyr Pharma (ATYR) - Stock Titan
aTyr Pharma, Inc. (ATYR) Investor Outlook: Exploring a Potential 445% Upside in the Biotech Sector - DirectorsTalk Interviews
aTyr Pharma, Inc. (NASDAQ:ATYR) Given Average Recommendation of "Hold" by Analysts - MarketBeat
ATyr Pharma Announces Scheduling of FDA Type - Moomoo
HC Wainwright & Co. Downgrades aTyr Pharma (ATYR) - MSN
aTyr Pharma Inc Stock (ISIN: US53227K1025) Faces Uncertainty Amid Delisting Risk and Pipeline Focus - AD HOC NEWS
aTyr Pharma (NASDAQ:ATYR) Upgraded at Wall Street Zen - MarketBeat
Does aTyr Pharma Inc stock benefit from AI growth2026 Analyst Calls & Precise Entry and Exit Recommendations - baoquankhu1.vn
aTyr Pharma (NASDAQ: ATYR) asks shareholders to double authorized shares to 340M - Stock Titan
aTyr Pharma Spotlights Efzofitimod Phase 3 Learnings, Eyes Mid-April FDA Type C Meeting - MarketBeat
ATYR: Efzofitimod shows durable quality of life gains and is reshaping sarcoidosis treatment practices - TradingView
Investigation announced for Long-Term Investors in shares - openPR.com
aTyr Pharma (ATYR) Receives a Buy from Piper Sandler - The Globe and Mail
Atyr to discuss efzofitimod’s future with FDA after Phase 3 sarcoidosis trial - Sarcoidosis News
Q1 Earnings Estimate for aTyr Pharma Issued By HC Wainwright - MarketBeat
Atyr Pharma Faces Nasdaq Delisting Risk After Minimum Bid Price Violation - The Globe and Mail
Jefferies Maintains Buy on ATYR aTyr Pharma, Inc. March 2026 - Meyka
Jefferies reiterates aTyr Pharma stock rating on regulatory outlook By Investing.com - Investing.com Canada
Jefferies reiterates aTyr Pharma stock rating on regulatory outlook - Investing.com UK
aTyr Pharma 2025 Financials: Q4 Loss Narrows, Annual Revenue SteadyNews and Statistics - IndexBox
Atyr Pharma: Fourth Quarter Earnings Overview - Bitget
aTyr Pharma (NASDAQ:ATYR) Posts Quarterly Earnings Results, Beats Expectations By $0.04 EPS - MarketBeat
aTyr (ATYR) Achieves Milestone with Phase 3 Study Results - GuruFocus
aTyr Pharma Announces Fourth Quarter and Full Year 2025 Results and Provides Corporate Update - The Manila Times
Atyr Pharma: Q4 Earnings Snapshot - marketscreener.com
ATyr Pharma Announces Fourth Quarter and Full Year 2025 Results and Provides Corporate Update - marketscreener.com
Why Is aTyr Stock Falling Today? - Stocktwits
aTyr Pharma (ATYR) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Atyr Pharma Inc (ATYR) 財務データ
収益
当期純利益
現金流量
EPS
Atyr Pharma Inc (ATYR) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Broadfoot Jill Marie | Chief Financial Officer |
Feb 04 '26 |
Sale |
0.98 |
1,558 |
1,521 |
37,296 |
| DENYES NANCY | General Counsel |
Feb 04 '26 |
Sale |
0.98 |
1,118 |
1,091 |
33,124 |
| SCHIMMEL PAUL | Director |
Oct 08 '25 |
Buy |
0.90 |
682,001 |
612,437 |
1,095,024 |
| SCHIMMEL PAUL | Director |
Oct 09 '25 |
Buy |
0.94 |
317,999 |
299,364 |
1,413,023 |
5.78%
0.81%
大文字化:
|
ボリューム (24 時間):